FRD vs REGN · P/E 19, $116.9M cap vs P/E 14, rev $14.34B
Friedman Industries Inc. Common Stock (FRD) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Friedman Industries Inc. Common Stock (FRD) is a steel company listed on US.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
FRD does not have a complete income-statement cache yet.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
FRD currently screens at market cap $116.9M and trailing P/E 19.0. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the FRD and REGN stock pages for the full models.
Not investment advice.